Table 5.
GRADE evidence profile.
| Indicators (Trials) | Quality assessment | Malignant pleural effusion | Clinical efficacy and safety | Quality | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Rh-endostatin | Chemical irritants | Odds ratios (95% CI) | Absolute effects | ||
| Rh-Endostatin with Cisplatin | ||||||||||
| Complete response (59) | Serious1 | None | None | None | None2 | 521/1882 (27.7%) | 282/1870 (15.1%) | 2.29(1.93 to 2.71) | 138 more per 1000 (from 104 more to 174 more) | ÅÅÅO |
| Treatment Failure (60) | Serious1 | None | None | None | None3 | 493/1906 (25.9%) | 996/1894 (52.6%) | 0.29(0.25 to 0.33) | 283 fewer per 1000 (from 258 fewer to 309 fewer) | ÅÅÅO |
| progressive disease (50) | Serious1 | None | None | None | None3 | 141/1629 (8.7%) | 387/1609 (24.1%) | 0.27(0.22 to 0.34) | 162 fewer per 1000 (from 143 fewer to 175 fewer) | ÅÅÅO |
| One year OS rate (3) | Serious1 | None | None | Serious4 | None | 46/69 (66.7%) | 24/64 (37.5%) | 3.32(1.63 to 6.75) | 291 more per 1000 (from 119 more to 427 more) | ÅÅOO |
| Quality of life (32) | Serious1 | None | None | None | None2 | 729/1030 (70.8%) | 464/1014 (45.8%) | 3.01(2.49 to 3.63) | 260 more per 1000 (from 220 more to 296 more) | ÅÅÅO |
| Neutropenia (32) | Serious1 | None | None | None | None | 302/971 (31.1%) | 299/967 (30.9%) | 0.98(0.79 to 1.21) | 4 fewer per 1000 (from 48 fewer to 42 more) | ÅÅÅO |
| Thrombocytopenia (28) | Serious1 | None | None | None | None | 187/875 (21.4%) | 178/868 (20.5%) | 1.04(0.8 to 1.36) | 6 more per 1000 (from 34 fewer to 55 more) | ÅÅÅO |
| Thrombocytopenia (10) | Serious1 | None | None | None | None | 49/337 (14.5%) | 40/339 (11.8%) | 1.29(0.8 to 2.09) | 29 more per 1000 (from 21 fewer to 101 more) | ÅÅÅO |
| Cardiotoxicity (21) | Serious1 | None | None | None | None | 37/671 (5.5%) | 27/672 (4%) | 1.39(0.84 to 2.31) | 15 more per 1000 (from 6 fewer to 48 more) | ÅÅÅO |
| Hepatotoxicity (28) | Serious1 | None | None | None | None | 91/898 (10.1%) | 85/900 (9.4%) | 1.07(0.77 to 1.48) | 6 more per 1000 (from 20 fewer to 39 more) | ÅÅÅO |
| Nephrotoxicity (28) | Serious1 | None | None | None | None | 68/886 (7.7%) | 65/890 (7.3%) | 1.06(0.74 to 1.53) | 4 more per 1000 (from 18 fewer to 35 more) | ÅÅÅO |
| Nausea and vomiting (49) | Serious1 | None | None | None | None | 436/1554 (28.1%) | 397/1538 (25.8%) | 1.14(0.95 to 1.36) | 26 more per 1000 (from 10 fewer to 63 more) | ÅÅÅO |
| Chest pain (12) | Serious1 | None | None | None | None | 51/316 (16.1%) | 50/321 (15.6%) | 1.01(0.63 to 1.6) | 1 more per 1000 (from 52 fewer to 72 more) | ÅÅÅO |
| Fever (20) | Serious1 | None | None | None | None | 67/578 (11.6%) | 68/573 (11.9%) | 0.98(0.68 to 1.41) | 2 fewer per 1000 (from 35 fewer to 41 more) | ÅÅÅO |
| Alopecia (2) | Serious5 | None | None | Serious4 | None | 5/63 (7.9%) | 4/61 (6.6%) | 1.22(0.33 to 4.54) | 13 more per 1000 (from 43 fewer to 176 more) | ÅÅOO |
| Neurotoxicity (5) | Serious1 | None | None | None | None | 8/175 (4.6%) | 8/173 (4.6%) | 0.98(0.36 to 2.65) | 1 fewer per 1000 (from 29 fewer to 68 more) | ÅÅÅO |
| Rash (5) | Serious5 | None | None | None | None | 17/193 (8.8%) | 11/186 (5.9%) | 1.57(0.71 to 3.5) | 31 more per 1000 (from 16 fewer to 121 more) | ÅÅÅO |
| Hypertension (3) | Serious1 | None | None | Serious4 | None | 5/92 (5.4%) | 0/84 (0%) | 4.13(0.68 to 25.1) | none | ÅÅOO |
| Hemorrhage (2) | Serious1 | None | None | Serious4 | None | 4/70 (5.7%) | 1/66 (1.5%) | 2.95(0.45 to 19.5) | 28 more per 1000 (from 8 fewer to 215 more) | ÅÅOO |
| Rh-Endostatin with Nedaplatin | ||||||||||
| Complete response (4) | Serious1 | None | None | Serious4 | None | 37/117 (31.6%) | 19/117 (16.2%) | 2.5(1.31 to 4.77) | 164 more per 1000 (from 40 more to 318 more) | ÅÅOO |
| Treatment failure (4) | Serious1 | None | None | Serious4 | None | 26/117 (22.2%) | 57/117 (48.7%) | 0.29(0.16 to 0.51) | 271 fewer per 1000 (from 161 fewer to 355 fewer) | ÅÅOO |
| Progressive disease (3) | Very serious6 | None | None | Serious4 | None | 7/89 (7.9%) | 19/89 (21.3%) | 0.31(0.12 to 0.79) | 136 fewer per 1000 (from 37 fewer to 182 fewer) | ÅOOO |
| Rh-Endostatin with Carboplatin | ||||||||||
| Complete response (2) | Very serious7 | None | None | Serious4 | None | 20/56 (35.7%) | 12/53 (22.6%) | 1.99(0.84 to 4.71) | 142 more per 1000 (from 29 fewer to 353 more) | ÅOOO |
| Treatment failure (2) | Very serious7 | None | None | Serious4 | None | 16/56 (28.6%) | 30/53 (56.6%) | 0.28(0.12 to 0.64) | 299 fewer per 1000 (from 111 fewer to 431 fewer) | ÅOOO |
| Progressive disease (2) | Very serious7 | None | None | Serious4 | None | 8/56 (14.3%) | 19/53 (35.8%) | 0.25(0.09 to 0.67) | 236 fewer per 1000 (from 86 fewer to 311 fewer) | ÅOOO |
| Rh-Endostatin with Lobaplatin | ||||||||||
| Complete response (3) | Very serious7 | None | None | Serious4 | None | 33/124 (26.6%) | 15/124 (12.1%) | 2.71(1.37 to 5.35) | 151 more per 1000 (from 38 more to 303 more) | ÅOOO |
| Treatment failure (3) | Very serious7 | None | None | Serious4 | None | 30/124 (24.2%) | 68/124 (54.8%) | 0.25(0.15 to 0.44) | 316 fewer per 1000 (from 200 fewer to 394 fewer) | ÅOOO |
| Progressive disease (2) | Very serious7 | None | None | Serious4 | None | 7/74 (9.5%) | 17/74 (23%) | 0.32(0.12 to 0.86) | 143 fewer per 1000 (from 26 fewer to 195 fewer) | ÅOOO |
| Rh-Endostatin with Bleomycin | ||||||||||
| Complete response (4) | Serious1 | None | None | Serious4 | None | 32/103 (31.1%) | 18/92 (19.6%) | 1.95(0.99 to 3.83) | 126 more per 1000 (from 2 fewer to 287 more) | ÅÅOO |
| Treatment failure (4) | Serious1 | None | None | Serious4 | None | 16/103 (15.5%) | 38/92 (41.3%) | 0.25(0.13 to 0.5) | 263 fewer per 1000 (from 153 fewer to 329 fewer) | ÅÅOO |
| Progressive disease (4) | Very serious6 | None | None | Serious4 | None | 6/103 (5.8%) | 16/92 (17.4%) | 0.31(0.12 to 0.8) | 113 fewer per 1000 (from 30 fewer to 149 fewer) | ÅOOO |
CI, confidence interval; OS, overall survival;,Rh-endostatin, recombinant human endostatin.1Most trials had an unclear risk, and some trials had a high risk. If good robustness, we downgraded it by one grade. 2Publication bias was found in them, and the result was overestimated. The result showed good robustness and was not downgraded. 3Publication bias was found in them, and the result was underestimated. The result showed good robustness and not downgraded. 4The number of patients in each result was less than 300, and we downgraded it by one grade. 5Most trials had an unclear risk and no high risk, and we downgraded it by one grade. 6Most trials had an unclear risk, and some trials had a high risk. If sensitivity analysis results had poor robustness, we downgraded it by two grades. 7All trials had a high risk, and we downgraded it by two grades.